172.5K XNAS Volume
XNAS 27 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Pomerantz J. Roger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 9,034 | 18,069 | - | - | Restricted Stock Units | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 25,219 | 839,741 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 9,034 | 126,478 | - | 0 | Common Stock | |
| Royston Ivor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 25,219 | 50,438 | - | - | Restricted Stock Units | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2024 | 25,219 | 814,522 | - | 0 | Common Stock | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2024 | 25,219 | 75,657 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2024 | 9,034 | 27,103 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2024 | 9,034 | 117,444 | - | 0 | Common Stock | |
| Ivor Royston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Darcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Pomerantz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Pomerantz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 18,750 | 18,750 | - | - | Stock Option (Right to Buy) | |
| Barry J. Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Jane F. Barlow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Stephen Rubino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Flavia Borellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 25,219 | 789,303 | - | 0 | Common Stock | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 25,219 | 100,876 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 9,035 | 36,137 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 9,035 | 108,410 | - | 0 | Common Stock | |
| Mark Andrew Rothera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 475,000 | 475,000 | - | - | Stock Option (Right to Buy) | |
| Daniel R. Chevallard | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Darrel P. Cohen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Chevallard R. Daniel | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 6,889 | 105,711 | - | 0 | Common Stock | |
| Royston Ivor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 25,219 | 126,095 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 9,034 | 99,375 | - | 0 | Common Stock | |
| R. Daniel Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 6,889 | 34,444 | - | - | Restricted Stock Units | |
| R. Daniel Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 0.73 per share. | 25 Feb 2024 | 3,405 | 102,306 | - | 0.7 | 2,493 | Common Stock |
| Pomerantz J. Roger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 9,034 | 45,172 | - | - | Restricted Stock Units | |
| Royston Ivor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 25,219 | 764,084 | - | 0 | Common Stock | |
| Rothera Andrew Mark | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.49 per share. | 30 Nov 2023 | 47,906 | 100,000 | - | 0.5 | 23,627 | Common Stock |
| Rothera Mark Andrew | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.49 per share. | 30 Nov 2023 | 52,094 | 52,094 | - | 0.5 | 25,734 | Common Stock |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 25,219 | 176,533 | - | - | Restricted Stock Units | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 25,219 | 713,646 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 9,034 | 81,307 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 9,034 | 63,240 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 6,888 | 99,165 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 6,888 | 48,222 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.45 per share. | 25 Aug 2023 | 3,512 | 95,653 | - | 1.4 | 5,092 | Common Stock |
| Roger J. Pomerantz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Darrel P. Cohen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 235,000 | 235,000 | - | - | Stock Option (Right to Buy) | |
| Darrel P. Cohen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 265,000 | 265,000 | - | - | Stock Option (Right to Buy) | |
| Ivor Royston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Darcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Pomerantz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Barry J. Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Jane F. Barlow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Stephen Rubino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Flavia Borellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Mark Andrew Rothera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Daniel R. Chevallard | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Lisa Rojkjaer | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 25,219 | 663,208 | - | 0 | Common Stock | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 25,219 | 226,971 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 9,034 | 81,309 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 9,034 | 63,238 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 25 Feb 2023 | 3,599 | 89,023 | - | 1.7 | 6,051 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 6,889 | 92,622 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 6,889 | 61,999 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 25 Feb 2023 | 2,156 | 48,087 | - | 1.7 | 3,625 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 4,127 | 37,146 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 4,127 | 50,243 | - | 0 | Common Stock | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 25,219 | 637,989 | - | 0 | Common Stock | |
| Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 25,219 | 252,190 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 9,034 | 54,204 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 9,034 | 90,343 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 2.72 per share. | 25 Nov 2022 | 3,532 | 85,733 | - | 2.7 | 9,606 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 6,889 | 89,265 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 6,889 | 68,888 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 4,127 | 48,232 | - | 0 | Common Stock | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 4,127 | 41,273 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.72 per share. | 25 Nov 2022 | 2,116 | 46,116 | - | 2.7 | 5,754 | Common Stock |
| Mark Andrew Rothera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 1,375,000 | 1,375,000 | - | - | Stock Option (Right to Buy) | |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 25,219 | 626,149 | - | 0 | Common Stock | |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 25,219 | 277,409 | - | - | Restricted Stock Units | |
| Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 4.01 per share. | 25 Aug 2022 | 13,379 | 612,770 | - | 4.0 | 53,656 | Common Stock |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 9,034 | 45,170 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 9,034 | 99,377 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 4.02 per share. | 25 Aug 2022 | 3,655 | 82,376 | - | 4.0 | 14,679 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 6,889 | 86,031 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 6,889 | 75,777 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 4,127 | 45,400 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.01 per share. | 25 Aug 2022 | 2,190 | 44,105 | - | 4.0 | 8,786 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 4,127 | 46,295 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 30,282 | 30,282 | - | - | Stock Option (Right to Buy) | |
| Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Darcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Nicole Onetto | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Pomerantz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Barry J. Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Jane F. Barlow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Michael Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Stephen Rubino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Flavia Borellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 1.90 per share. | 25 May 2022 | 13,162 | 600,930 | - | 1.9 | 25,022 | Common Stock |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 25,219 | 302,628 | - | - | Restricted Stock Units | |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 25,219 | 614,092 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 9,034 | 108,411 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 9,034 | 36,136 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 6,889 | 82,666 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.90 per share. | 25 May 2022 | 3,596 | 79,142 | - | 1.9 | 6,836 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 6,889 | 82,738 | - | 0 | Common Stock | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 4,127 | 49,527 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 4,127 | 44,322 | - | 0 | Common Stock | |
| Lisa Rojkjaer | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.90 per share. | 25 May 2022 | 2,154 | 42,168 | - | 1.9 | 4,095 | Common Stock |
| Ivor Royston | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 412,500 | 412,500 | - | - | Stock Option (Right to Buy) | |
| Daniel R. Chevallard | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Lisa Rojkjaer | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 25,219 | 603,508 | - | 0 | Common Stock | |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 25,219 | 327,847 | - | - | Restricted Stock Units | |
| Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 2.78 per share. | 25 Feb 2022 | 14,635 | 588,873 | - | 2.8 | 40,678 | Common Stock |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 9,034 | 27,102 | - | 0 | Common Stock | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 9,034 | 117,445 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 6,889 | 89,555 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 6,889 | 79,847 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 2.78 per share. | 25 Feb 2022 | 3,998 | 75,849 | - | 2.8 | 11,112 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 4,127 | 53,654 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 4,127 | 42,590 | - | 0 | Common Stock | |
| Lisa Rojkjaer | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.78 per share. | 25 Feb 2022 | 2,395 | 40,195 | - | 2.8 | 6,657 | Common Stock |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 29 Dec 2021 | 7,000 | 578,289 | - | 0.9 | 6,300 | Common Stock |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2021 | 7,000 | 60,800 | - | - | Stock Option (Right to Buy) | |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 50,437 | 599,036 | - | 0 | Common Stock | |
| Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 25 Nov 2021 | 11,914 | 587,122 | - | 4.8 | 57,194 | Common Stock |
| Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 4.82 per share. | 25 Nov 2021 | 15,833 | 571,289 | - | 4.8 | 76,301 | Common Stock |
| Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 50,437 | 353,066 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 18,068 | 126,479 | - | - | Restricted Stock Units | |
| Roger J. Pomerantz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 18,068 | 18,068 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 13,777 | 96,444 | - | - | Restricted Stock Units | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 13,777 | 80,537 | - | 0 | Common Stock | |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 25 Nov 2021 | 3,254 | 77,283 | - | 4.8 | 15,621 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 4.82 per share. | 25 Nov 2021 | 4,325 | 72,958 | - | 4.8 | 20,843 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 8,254 | 57,781 | - | - | Restricted Stock Units | |
| Lisa Rojkjaer | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.82 per share. | 25 Nov 2021 | 2,591 | 38,463 | - | 4.8 | 12,486 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 25 Nov 2021 | 1,950 | 41,054 | - | 4.8 | 9,361 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 8,254 | 43,004 | - | 0 | Common Stock | |
| Ivor Royston | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 5.56 per share. | 15 Nov 2021 | 8,000 | 548,599 | - | 5.6 | 44,480 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 28 Sep 2021 | 10,000 | 66,760 | - | 0.9 | 9,000 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2021 | 10,000 | 88,817 | - | - | Stock Option (Right to Buy) | |
| Jane F. Barlow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Flavia Borellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 28 May 2021 | 12,000 | 56,760 | - | 0.9 | 10,800 | Common Stock |
| Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 12,000 | 98,817 | - | - | Stock Option (Right to Buy) | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.58 per share. | 11 May 2021 | 2,061 | 34,750 | - | 3.6 | 7,378 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.26 per share. | 11 May 2021 | 32,689 | 32,689 | - | 1.3 | 41,188 | Common Stock |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 32,689 | 98,069 | - | - | Stock Option (Right to Buy) | |
| Lisa Rojkjaer | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 2,061 | 30,956 | - | - | Stock Option (Right to Buy) |